CAM
GBT

Cresset Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Cresset Asset Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-110
Closed -$6K – 1887
2019
Q1 		$6K Hold
110
– – ﹤0.01% 1331
2018
Q4 		$5K Buy
+110
New +$4.12K ﹤0.01% 1053

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cresset Asset Management's GBT Position: Q2 2019 in Review

Cresset Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2019, closing a stake of 110 shares — an estimated $6K sold.

Cresset Asset Management first reported a position in GBT in Q4 2018 and held it in 2 quarters. The position peaked at $6K in Q1 2019. 223 funds tracked by Wall St. Rank hold GBT as of Q2 2019.

  • Cresset Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Cresset Asset Management sold 110 Global Blood Therapeutics, Inc. shares in Q2 2019, an estimated $6K.
  • Cresset Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2018 and held it in 2 quarters.
  • Cresset Asset Management's Global Blood Therapeutics, Inc. position peaked at $6K in Q1 2019.
  • 223 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2019.

Based on Cresset Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.